OR54: The Reve Study, Preliminary Results. A Monocentric Single-Arm Study to Characterize the Long-Term Safety and Efficacy of GLP-2 Analog (Teduglutide) in the Management of Short Bowel Syndrome in Pediatric Patients on Home-Parenteral Nutrition

2019 ◽  
Vol 38 ◽  
pp. S25
Author(s):  
C. Lambe ◽  
C. Talbotec ◽  
N. Kapel ◽  
O. Goulet
2014 ◽  
Vol 58 (4) ◽  
pp. 438-442 ◽  
Author(s):  
Antonella Diamanti ◽  
Andrea Conforti ◽  
Fabio Panetta ◽  
Giuliano Torre ◽  
Manila Candusso ◽  
...  

2004 ◽  
Vol 39 (Supplement 1) ◽  
pp. S349
Author(s):  
V. Colomb ◽  
M. Dabbas ◽  
C. Talbotec ◽  
P. Taupin ◽  
O. Corriol ◽  
...  

2012 ◽  
Vol 23 (4) ◽  
pp. 451-464 ◽  
Author(s):  
Anne Gargasz

Parenteral nutrition is one of the most important therapeutic modalities invented in the last several decades. Since its introduction in the 1960s, this modality has saved thousands of lives by providing nutrients parenterally to sustain growth in premature neonates with severe intestinal immaturity and other pediatric patients with intestinal failure, such as a gastrointestinal fistula or short bowel syndrome. Although parenteral nutrition can be a lifesaving treatment, it is not benign. Many complications can result from either short- or long-term usage. This review discusses the nutritional requirements, common complications, medication additives, and special considerations for pediatric patients requiring parenteral nutrition.


2020 ◽  
Vol 2 (4) ◽  
Author(s):  
Zeinab Bakhshi ◽  
Siddhant Yadav ◽  
Bradley R Salonen ◽  
Sara L Bonnes ◽  
Jithinraj Edakkanambeth Varayil ◽  
...  

Abstract Background We sought to estimate the incidence of home parenteral nutrition (HPN) use in a population-based cohort of patients with Crohn disease (CD), and to assess clinical outcomes and complications associated with HPN. Methods We used the Rochester Epidemiology Project (REP) to identify residents of Olmsted County, who were diagnosed with CD between 1970 and 2011, and required HPN. Results Fourteen out of 429 patients (3.3%) with CD received HPN (86% female). Eleven patients (79%) had moderate–severe CD and 12 patients (86%) had fistulizing disease. Thirteen patients (93%) underwent surgery, primarily due to obstruction. Among CD incidence cases, the cumulative incidence of HPN from the date of CD diagnosis was 0% at 1 year, 0.5% at 5 years, 0.8% at 10 years, and 2.4% at 20 years. Indications for HPN included short bowel syndrome in 64%, malnutrition in 29%, and bowel rest in 21%. The median duration of HPN was 2.5 years. There was an average weight gain of 1.2 kg at 6 months, an average weight loss of 1.4 kg at 1 year, and a further weight loss of 2.2 kg at 2 years from the start of HPN. Patients were hospitalized a mean of 5 times after the start of HPN, mainly due to catheter-related bloodstream infections and thrombosis. Conclusions Less than 4% of patients with CD need HPN. Most have moderate to severe disease with short bowel syndrome or malnutrition. Possible reasons for the patients’ weight loss could be noncompliance, and increased metabolic needs because of active disease.


2003 ◽  
Vol 124 (2) ◽  
pp. 293-302 ◽  
Author(s):  
David Seguy ◽  
Kouroche Vahedi ◽  
Nathalie Kapel ◽  
Jean–Claude Souberbielle ◽  
Bernard Messing

Sign in / Sign up

Export Citation Format

Share Document